Thursday, June 27 and Friday, June 28 Evaluation

Question Title

* 1. Please select your designation(s):

PhD

Other (please specify)

Question Title

* 2. Please indicate your specialties:

Allergy

Asthma

Autoimmunity

Cell Biology

Dermatology

Diabetes

Endocrinology

Flow Cytometry

Gastroenterology

Genetics

Hematology

Infectious Disease

Inflammation

Microbiology

Molecular & Cellular Biology

Multiple Sclerosis

Neuroimmunology

Neurology

Oncology

Pathology

Pharmacology

Primary Immuno-deficiency

Rheumatology

Transplantation

Uveitis

Question Title

* 3. Please select the categories you most identify with:

Trainee/Fellow

Industry

Academic Faculty

Clinician

Question Title

* 4. Thursday, June 27, 5:30-6:30 pm
Opening Keynote Address: T Cell Control of HIV - Bruce Walker, MD

	Disagree	Undecided	Agree	Did not Attend
I will make changes in my practice/profession as a result of what I learned in this session.	I will make changes in my practice/profession as a result of what I learned in this session. Disagree	I will make changes in my practice/profession as a result of what I learned in this session. Undecided	I will make changes in my practice/profession as a result of what I learned in this session. Agree	I will make changes in my practice/profession as a result of what I learned in this session. Did not Attend

Question Title

* 5. After participating in this session, are you able to:

	Yes	No
Discuss the role of CD8 T cells in immune control	Discuss the role of CD8 T cells in immune control Yes	Discuss the role of CD8 T cells in immune control No
Discuss the effect of clonotype on TCR-peptide-MHC interaction	Discuss the effect of clonotype on TCR-peptide-MHC interaction Yes	Discuss the effect of clonotype on TCR-peptide-MHC interaction No

Question Title

* 6. Please rate the quality of this presentation.

Excellent

Good

Average

Poor

Comments

Question Title

* 7. Did you perceive bias in this presentation?

Yes

If yes, please specify

Question Title

* 8. Friday, June 28, 8:00-9:45 am
Plenary Session: Targeting Signalling Pathways in Inflammatory Disease

	Disagree	Undecided	Agree	Did not attend
I will make changes in my practice as a result of what I learned in this session.	I will make changes in my practice as a result of what I learned in this session. Disagree	I will make changes in my practice as a result of what I learned in this session. Undecided	I will make changes in my practice as a result of what I learned in this session. Agree	I will make changes in my practice as a result of what I learned in this session. Did not attend

Question Title

* 9. After participating in this session, are you able to:

	Yes	No
Discuss the current status of JAK inhibitors and describe their mechanism of action	Discuss the current status of JAK inhibitors and describe their mechanism of action Yes	Discuss the current status of JAK inhibitors and describe their mechanism of action No
Extrapolate the future for this class of immunodulatory agents	Extrapolate the future for this class of immunodulatory agents Yes	Extrapolate the future for this class of immunodulatory agents No
Describe how antigen receptor signaling is initiated and controlled	Describe how antigen receptor signaling is initiated and controlled Yes	Describe how antigen receptor signaling is initiated and controlled No
Illustrate how intervening at certain points in antigen receptor pathways can block certain functions	Illustrate how intervening at certain points in antigen receptor pathways can block certain functions Yes	Illustrate how intervening at certain points in antigen receptor pathways can block certain functions No
Report on therapies in development or in clinical trials that target tyrosine kinases in antigen receptor pathways	Report on therapies in development or in clinical trials that target tyrosine kinases in antigen receptor pathways Yes	Report on therapies in development or in clinical trials that target tyrosine kinases in antigen receptor pathways No
Explain the P13K singalling pathway and pre-clinical progress in the development of P13K to treat autoimmune and inflammatory disease	Explain the P13K singalling pathway and pre-clinical progress in the development of P13K to treat autoimmune and inflammatory disease Yes	Explain the P13K singalling pathway and pre-clinical progress in the development of P13K to treat autoimmune and inflammatory disease No

Question Title

* 10. Please rate the quality of the presentations:

	Excellent	Good	Average	Poor
Back to the Future: Jakinibs and Oral Targeted Therapy - John J. O'Shea, MD	Back to the Future: Jakinibs and Oral Targeted Therapy - John J. O'Shea, MD Excellent	Back to the Future: Jakinibs and Oral Targeted Therapy - John J. O'Shea, MD Good	Back to the Future: Jakinibs and Oral Targeted Therapy - John J. O'Shea, MD Average	Back to the Future: Jakinibs and Oral Targeted Therapy - John J. O'Shea, MD Poor
Regulating Tyrosine Phosphorylation by Antigen Receptors - Arthur Weiss, MD, PhD	Regulating Tyrosine Phosphorylation by Antigen Receptors - Arthur Weiss, MD, PhD Excellent	Regulating Tyrosine Phosphorylation by Antigen Receptors - Arthur Weiss, MD, PhD Good	Regulating Tyrosine Phosphorylation by Antigen Receptors - Arthur Weiss, MD, PhD Average	Regulating Tyrosine Phosphorylation by Antigen Receptors - Arthur Weiss, MD, PhD Poor
P13K's in Immunity and Inflammation - Klaus Okkenhaug, PhD	P13K's in Immunity and Inflammation - Klaus Okkenhaug, PhD Excellent	P13K's in Immunity and Inflammation - Klaus Okkenhaug, PhD Good	P13K's in Immunity and Inflammation - Klaus Okkenhaug, PhD Average	P13K's in Immunity and Inflammation - Klaus Okkenhaug, PhD Poor

Comments

Question Title

* 11. Did you perceive bias in any of the session presentations?

	Yes	No
Back to the Future: Jakinibs and Oral Targeted Therapy - John J. O'Shea, MD	Back to the Future: Jakinibs and Oral Targeted Therapy - John J. O'Shea, MD Yes	Back to the Future: Jakinibs and Oral Targeted Therapy - John J. O'Shea, MD No
Regulating Tyrosine Phosphorylation by Antigen Receptors - Aurthur Weiss, MD, PhD	Regulating Tyrosine Phosphorylation by Antigen Receptors - Aurthur Weiss, MD, PhD Yes	Regulating Tyrosine Phosphorylation by Antigen Receptors - Aurthur Weiss, MD, PhD No
P13K's in Immunity and Inflammation - Klaus Okkenhaug, PhD	P13K's in Immunity and Inflammation - Klaus Okkenhaug, PhD Yes	P13K's in Immunity and Inflammation - Klaus Okkenhaug, PhD No

If yes, please specify

Question Title

* 12. Friday, June 28, 10:00-11:45 am
Plenary Session: Removing the Brakes on Anti-Tumor Immune Responses

	Disagree	Undecided	Agree	Did not attend
I will make changes in my practice/profession as a result of what I learned in this session.	I will make changes in my practice/profession as a result of what I learned in this session. Disagree	I will make changes in my practice/profession as a result of what I learned in this session. Undecided	I will make changes in my practice/profession as a result of what I learned in this session. Agree	I will make changes in my practice/profession as a result of what I learned in this session. Did not attend

Question Title

* 13. After participating in this session, are you able to:

	Yes	No
Describe the role of T cells in cancer	Describe the role of T cells in cancer Yes	Describe the role of T cells in cancer No
Describe immune suppressive mechanisms in cancer	Describe immune suppressive mechanisms in cancer Yes	Describe immune suppressive mechanisms in cancer No
Discuss current challenges in R&D for optimizing cancer immunotherapy	Discuss current challenges in R&D for optimizing cancer immunotherapy Yes	Discuss current challenges in R&D for optimizing cancer immunotherapy No
Distinguish the mechanism of action and treatment outcomes of the PD-1 blockade in cancer	Distinguish the mechanism of action and treatment outcomes of the PD-1 blockade in cancer Yes	Distinguish the mechanism of action and treatment outcomes of the PD-1 blockade in cancer No

Question Title

* 14. Please rate the quality of the session presentations:

	Excellent	Good	Average	Poor
T Cell Function in the Tumor Micro- and Macro-Environments - Daniel Speiser, MD	T Cell Function in the Tumor Micro- and Macro-Environments - Daniel Speiser, MD Excellent	T Cell Function in the Tumor Micro- and Macro-Environments - Daniel Speiser, MD Good	T Cell Function in the Tumor Micro- and Macro-Environments - Daniel Speiser, MD Average	T Cell Function in the Tumor Micro- and Macro-Environments - Daniel Speiser, MD Poor
PD-1 Pathway Blockade: Mobilizing the Immune System to Treat Cancer - Suzanne Topalian, MD	PD-1 Pathway Blockade: Mobilizing the Immune System to Treat Cancer - Suzanne Topalian, MD Excellent	PD-1 Pathway Blockade: Mobilizing the Immune System to Treat Cancer - Suzanne Topalian, MD Good	PD-1 Pathway Blockade: Mobilizing the Immune System to Treat Cancer - Suzanne Topalian, MD Average	PD-1 Pathway Blockade: Mobilizing the Immune System to Treat Cancer - Suzanne Topalian, MD Poor
Title TBA - James Allison, PhD	Title TBA - James Allison, PhD Excellent	Title TBA - James Allison, PhD Good	Title TBA - James Allison, PhD Average	Title TBA - James Allison, PhD Poor

Comments

Question Title

* 15. Did you perceive bias in any of the session presentations?

	Yes	No
T Cell Function in the Tumor Micro- and Macro-Environments - Daniel Speiser, MD	T Cell Function in the Tumor Micro- and Macro-Environments - Daniel Speiser, MD Yes	T Cell Function in the Tumor Micro- and Macro-Environments - Daniel Speiser, MD No
PD-1 Pathway Blockade: Mobilizing the Immune System to Treat Cancer - Suzanne Topalian, MD	PD-1 Pathway Blockade: Mobilizing the Immune System to Treat Cancer - Suzanne Topalian, MD Yes	PD-1 Pathway Blockade: Mobilizing the Immune System to Treat Cancer - Suzanne Topalian, MD No
Title TBA - James Allison, PhD	Title TBA - James Allison, PhD Yes	Title TBA - James Allison, PhD No

If yes, please specify

Question Title

* 16. Friday, June 28, 1:15-3:00 pm
Concurrent Thematic Symposium: Innate Lymphoid Cells in Human Disease

	Disagree	Undecided	Agree	Did not attend
I will make changes in my practice/profession as a result of what I learned in this session.	I will make changes in my practice/profession as a result of what I learned in this session. Disagree	I will make changes in my practice/profession as a result of what I learned in this session. Undecided	I will make changes in my practice/profession as a result of what I learned in this session. Agree	I will make changes in my practice/profession as a result of what I learned in this session. Did not attend

Question Title

* 17. After participating in this session, are you able to:

	Yes	No
Identify various subsets of ILC	Identify various subsets of ILC Yes	Identify various subsets of ILC No
Discuss development and function of human ILC1 and ILC2	Discuss development and function of human ILC1 and ILC2 Yes	Discuss development and function of human ILC1 and ILC2 No
Discuss the possible role of ILC disease	Discuss the possible role of ILC disease Yes	Discuss the possible role of ILC disease No
Explain the concept of innate lymphoid cells (ILC) in immune responses	Explain the concept of innate lymphoid cells (ILC) in immune responses Yes	Explain the concept of innate lymphoid cells (ILC) in immune responses No
Examine the potential impact of ILC in human diseases, particularly inflammatory bowel disease	Examine the potential impact of ILC in human diseases, particularly inflammatory bowel disease Yes	Examine the potential impact of ILC in human diseases, particularly inflammatory bowel disease No
Discuss the immune pathways that regulate responses to infections, injury and inflammation at the body's barrier surfaces including the skin, lung and intestine	Discuss the immune pathways that regulate responses to infections, injury and inflammation at the body's barrier surfaces including the skin, lung and intestine Yes	Discuss the immune pathways that regulate responses to infections, injury and inflammation at the body's barrier surfaces including the skin, lung and intestine No

Question Title

* 18. Please rate the quality of the session presentations:

	Excellent	Good	Average	Poor
New Insights in Development and Function of Human Innate Lymphoid Cells - Hergen Spits, PhD	New Insights in Development and Function of Human Innate Lymphoid Cells - Hergen Spits, PhD Excellent	New Insights in Development and Function of Human Innate Lymphoid Cells - Hergen Spits, PhD Good	New Insights in Development and Function of Human Innate Lymphoid Cells - Hergen Spits, PhD Average	New Insights in Development and Function of Human Innate Lymphoid Cells - Hergen Spits, PhD Poor
Innate Lymphoid Cells in Mucosal Immunity - Marco Colonna, PhD	Innate Lymphoid Cells in Mucosal Immunity - Marco Colonna, PhD Excellent	Innate Lymphoid Cells in Mucosal Immunity - Marco Colonna, PhD Good	Innate Lymphoid Cells in Mucosal Immunity - Marco Colonna, PhD Average	Innate Lymphoid Cells in Mucosal Immunity - Marco Colonna, PhD Poor
Immune Regulation at Barrier Surfaces - David Artis, PhD	Immune Regulation at Barrier Surfaces - David Artis, PhD Excellent	Immune Regulation at Barrier Surfaces - David Artis, PhD Good	Immune Regulation at Barrier Surfaces - David Artis, PhD Average	Immune Regulation at Barrier Surfaces - David Artis, PhD Poor

Comments

Question Title

* 19. Did you perceive bias in any of the session presentations?

	Yes	No
New Insights in Development and Function of Human Innate Lymphoid Cells - Hergen Spits, PhD	New Insights in Development and Function of Human Innate Lymphoid Cells - Hergen Spits, PhD Yes	New Insights in Development and Function of Human Innate Lymphoid Cells - Hergen Spits, PhD No
Innate Lymphoid Cells in Mucosal Immunity - Marco Colonna, PhD	Innate Lymphoid Cells in Mucosal Immunity - Marco Colonna, PhD Yes	Innate Lymphoid Cells in Mucosal Immunity - Marco Colonna, PhD No
Immune Regulation at Barrier Surfaces - David Artis, PhD	Immune Regulation at Barrier Surfaces - David Artis, PhD Yes	Immune Regulation at Barrier Surfaces - David Artis, PhD No

If yes, please specify

Question Title

* 20. Friday, June 28, 1:15-3:00 pm
Concurrent Thematic Symposium: From Genes to Mechanisms

	Disagree	Undecided	Agree	Did not attend
I will make changes in my practice/profession as a result of what I learned in this session.	I will make changes in my practice/profession as a result of what I learned in this session. Disagree	I will make changes in my practice/profession as a result of what I learned in this session. Undecided	I will make changes in my practice/profession as a result of what I learned in this session. Agree	I will make changes in my practice/profession as a result of what I learned in this session. Did not attend

Question Title

* 21. After participating in this session, are you able to:

	Yes	No
Explain the tools that can be used to go from GWAS to biologic function	Explain the tools that can be used to go from GWAS to biologic function Yes	Explain the tools that can be used to go from GWAS to biologic function No
Describe how focused analysis of GWAS can define clinically relevant patient subgroups	Describe how focused analysis of GWAS can define clinically relevant patient subgroups Yes	Describe how focused analysis of GWAS can define clinically relevant patient subgroups No
Employ the use of transcriptomics to predict long-term outcome in immune-mediated disease	Employ the use of transcriptomics to predict long-term outcome in immune-mediated disease Yes	Employ the use of transcriptomics to predict long-term outcome in immune-mediated disease No
Associate over 30 common gene variants known to predispose to psoriasis	Associate over 30 common gene variants known to predispose to psoriasis Yes	Associate over 30 common gene variants known to predispose to psoriasis No
Explain the rare and common variants in CARD14 that lead to psoriasis and psoriatic arthritis	Explain the rare and common variants in CARD14 that lead to psoriasis and psoriatic arthritis Yes	Explain the rare and common variants in CARD14 that lead to psoriasis and psoriatic arthritis No
Describe how pathways altered in psoriasis susceptibility through genetic variation including those leading to NF-kB activation, T cell regulation, innate host defense and macrophage activation	Describe how pathways altered in psoriasis susceptibility through genetic variation including those leading to NF-kB activation, T cell regulation, innate host defense and macrophage activation Yes	Describe how pathways altered in psoriasis susceptibility through genetic variation including those leading to NF-kB activation, T cell regulation, innate host defense and macrophage activation No

Question Title

* 22. Please rate the quality of the session presentations:

	Excellent	Good	Average	Poor
From GWAS to Biology - David Hafler, MD	From GWAS to Biology - David Hafler, MD Excellent	From GWAS to Biology - David Hafler, MD Good	From GWAS to Biology - David Hafler, MD Average	From GWAS to Biology - David Hafler, MD Poor
Genomics and Patient Stratification in Autoimmunity: The End of the Beginning? Ken Smith, PhD	Genomics and Patient Stratification in Autoimmunity: The End of the Beginning? Ken Smith, PhD Excellent	Genomics and Patient Stratification in Autoimmunity: The End of the Beginning? Ken Smith, PhD Good	Genomics and Patient Stratification in Autoimmunity: The End of the Beginning? Ken Smith, PhD Average	Genomics and Patient Stratification in Autoimmunity: The End of the Beginning? Ken Smith, PhD Poor
Molecular Alterations Predisposing to Psoriasis Provide Insights into Disease Pathogenesis - Anne Bowcock, PhD	Molecular Alterations Predisposing to Psoriasis Provide Insights into Disease Pathogenesis - Anne Bowcock, PhD Excellent	Molecular Alterations Predisposing to Psoriasis Provide Insights into Disease Pathogenesis - Anne Bowcock, PhD Good	Molecular Alterations Predisposing to Psoriasis Provide Insights into Disease Pathogenesis - Anne Bowcock, PhD Average	Molecular Alterations Predisposing to Psoriasis Provide Insights into Disease Pathogenesis - Anne Bowcock, PhD Poor

Comments

Question Title

* 23. Did you perceive bias in any of the session presentations?

	Yes	No
From GWAS to Biology - David Hafler, MD	From GWAS to Biology - David Hafler, MD Yes	From GWAS to Biology - David Hafler, MD No
Genomics and Patient Stratification in Autoimmunity: The End of the Beginning? Ken Smith, PhD	Genomics and Patient Stratification in Autoimmunity: The End of the Beginning? Ken Smith, PhD Yes	Genomics and Patient Stratification in Autoimmunity: The End of the Beginning? Ken Smith, PhD No
Molecular Alterations Predisposing to Psoriasis Provide Insights into Disease Pathogenesis - Anne Bowcock, PhD	Molecular Alterations Predisposing to Psoriasis Provide Insights into Disease Pathogenesis - Anne Bowcock, PhD Yes	Molecular Alterations Predisposing to Psoriasis Provide Insights into Disease Pathogenesis - Anne Bowcock, PhD No

If yes, please specify

Question Title

* 24. Friday, June 28, 1:15-3:00 pm
Concurrent Thematic Symposium: B Cells in Immune Inflammation

	Disagree	Undecided	Agree	Did not attend
I will make changes to my practice/profession as a result of what I learned in this session.	I will make changes to my practice/profession as a result of what I learned in this session. Disagree	I will make changes to my practice/profession as a result of what I learned in this session. Undecided	I will make changes to my practice/profession as a result of what I learned in this session. Agree	I will make changes to my practice/profession as a result of what I learned in this session. Did not attend

Question Title

* 25. After participating in this session, are you able to:

	Yes	No
Contrast diseases in which B cell depletion has demonstrated efficacy and lack of efficacy	Contrast diseases in which B cell depletion has demonstrated efficacy and lack of efficacy Yes	Contrast diseases in which B cell depletion has demonstrated efficacy and lack of efficacy No
Explain the breadth of mechanisms by which B cells may contribute to human diseases	Explain the breadth of mechanisms by which B cells may contribute to human diseases Yes	Explain the breadth of mechanisms by which B cells may contribute to human diseases No
Discuss B cell function as antigen-presenting cells during pre-clinical EAE	Discuss B cell function as antigen-presenting cells during pre-clinical EAE Yes	Discuss B cell function as antigen-presenting cells during pre-clinical EAE No
Explain that B cells facilitate the induction of inflammatory mediators in the central nervous system	Explain that B cells facilitate the induction of inflammatory mediators in the central nervous system Yes	Explain that B cells facilitate the induction of inflammatory mediators in the central nervous system No
Relate that B cells differentially influence reactivation of Th1 and Th17 cells	Relate that B cells differentially influence reactivation of Th1 and Th17 cells Yes	Relate that B cells differentially influence reactivation of Th1 and Th17 cells No

Question Title

* 26. Please rate the quality of the session presentations:

	Excellent	Good	Average	Poor
Risk Alleles and Gene Mutations Alter the Establishment of Human B Cell Tolerance - Eric Meffre, PhD	Risk Alleles and Gene Mutations Alter the Establishment of Human B Cell Tolerance - Eric Meffre, PhD Excellent	Risk Alleles and Gene Mutations Alter the Establishment of Human B Cell Tolerance - Eric Meffre, PhD Good	Risk Alleles and Gene Mutations Alter the Establishment of Human B Cell Tolerance - Eric Meffre, PhD Average	Risk Alleles and Gene Mutations Alter the Establishment of Human B Cell Tolerance - Eric Meffre, PhD Poor
B Cells in Human Disease - Andrew Chan, MD, PhD	B Cells in Human Disease - Andrew Chan, MD, PhD Excellent	B Cells in Human Disease - Andrew Chan, MD, PhD Good	B Cells in Human Disease - Andrew Chan, MD, PhD Average	B Cells in Human Disease - Andrew Chan, MD, PhD Poor
How B Cells Influence Neuroinflammation in an Animal Model of Multiple Sclerosis - Joan Goverman, PhD	How B Cells Influence Neuroinflammation in an Animal Model of Multiple Sclerosis - Joan Goverman, PhD Excellent	How B Cells Influence Neuroinflammation in an Animal Model of Multiple Sclerosis - Joan Goverman, PhD Good	How B Cells Influence Neuroinflammation in an Animal Model of Multiple Sclerosis - Joan Goverman, PhD Average	How B Cells Influence Neuroinflammation in an Animal Model of Multiple Sclerosis - Joan Goverman, PhD Poor

Comments

Question Title

* 27. Did you perceive bias in any of the session presentations?

	Yes	No
Risk Alleles and Gene Mutations Alter the Establishment of Human B Cell Tolerance - Eric Meffre, PhD	Risk Alleles and Gene Mutations Alter the Establishment of Human B Cell Tolerance - Eric Meffre, PhD Yes	Risk Alleles and Gene Mutations Alter the Establishment of Human B Cell Tolerance - Eric Meffre, PhD No
B Cells in Human Disease - Andrew Chan, MD, PhD	B Cells in Human Disease - Andrew Chan, MD, PhD Yes	B Cells in Human Disease - Andrew Chan, MD, PhD No
How B Cells Influence Neuroinflammation in an Animal Model of Multiple Sclerosis - Joan Goverman, PhD	How B Cells Influence Neuroinflammation in an Animal Model of Multiple Sclerosis - Joan Goverman, PhD Yes	How B Cells Influence Neuroinflammation in an Animal Model of Multiple Sclerosis - Joan Goverman, PhD No

If yes, please specify

Question Title

* 28. Friday, June 28, 3:15-5:15 pm
Featured Course: Principles of Flow Cytometry for Immune Monitoring Part I

	Disagree	Undecided	Agree	Did not attend
I will make changes in my practice/profession as a result of what I learned in this session.	I will make changes in my practice/profession as a result of what I learned in this session. Disagree	I will make changes in my practice/profession as a result of what I learned in this session. Undecided	I will make changes in my practice/profession as a result of what I learned in this session. Agree	I will make changes in my practice/profession as a result of what I learned in this session. Did not attend

Question Title

* 29. After participating in this session, are you able to:

	Yes	No
Discuss the factors that contribute to variability in multicenter flow cytometry studies	Discuss the factors that contribute to variability in multicenter flow cytometry studies Yes	Discuss the factors that contribute to variability in multicenter flow cytometry studies No
Identify the steps that have been taken by different groups to control these factors	Identify the steps that have been taken by different groups to control these factors Yes	Identify the steps that have been taken by different groups to control these factors No
Cite the successes of the various consortia that have undertaken flow cytometry standardization, and what gaps still remain	Cite the successes of the various consortia that have undertaken flow cytometry standardization, and what gaps still remain Yes	Cite the successes of the various consortia that have undertaken flow cytometry standardization, and what gaps still remain No

Question Title

* 30. Please rate the quality of the session presentations:

	Excellent	Good	Average	Poor
EuroFlow Consortium - Jacques Van Dongen, MD, PhD	EuroFlow Consortium - Jacques Van Dongen, MD, PhD Excellent	EuroFlow Consortium - Jacques Van Dongen, MD, PhD Good	EuroFlow Consortium - Jacques Van Dongen, MD, PhD Average	EuroFlow Consortium - Jacques Van Dongen, MD, PhD Poor
Cancer Immunotherapy Immunoguiding Program - Cedrick Britten, PhD	Cancer Immunotherapy Immunoguiding Program - Cedrick Britten, PhD Excellent	Cancer Immunotherapy Immunoguiding Program - Cedrick Britten, PhD Good	Cancer Immunotherapy Immunoguiding Program - Cedrick Britten, PhD Average	Cancer Immunotherapy Immunoguiding Program - Cedrick Britten, PhD Poor
Cancer Immunotherapy Consortium - Sylvia Janetzi, MD	Cancer Immunotherapy Consortium - Sylvia Janetzi, MD Excellent	Cancer Immunotherapy Consortium - Sylvia Janetzi, MD Good	Cancer Immunotherapy Consortium - Sylvia Janetzi, MD Average	Cancer Immunotherapy Consortium - Sylvia Janetzi, MD Poor
EQAPOL (NIAID) - Tom Denny, MSc, M.Phil	EQAPOL (NIAID) - Tom Denny, MSc, M.Phil Excellent	EQAPOL (NIAID) - Tom Denny, MSc, M.Phil Good	EQAPOL (NIAID) - Tom Denny, MSc, M.Phil Average	EQAPOL (NIAID) - Tom Denny, MSc, M.Phil Poor
FOCIS ImmunoPhenotyping Consortium - Holden Maecker, PhD	FOCIS ImmunoPhenotyping Consortium - Holden Maecker, PhD Excellent	FOCIS ImmunoPhenotyping Consortium - Holden Maecker, PhD Good	FOCIS ImmunoPhenotyping Consortium - Holden Maecker, PhD Average	FOCIS ImmunoPhenotyping Consortium - Holden Maecker, PhD Poor

Comments

Question Title

* 31. Did you perceive bias in any of the session presentations?

	Yes	No
EuroFlow Consortium - Jacques Van Dongen, MD, PhD	EuroFlow Consortium - Jacques Van Dongen, MD, PhD Yes	EuroFlow Consortium - Jacques Van Dongen, MD, PhD No
Cancer Immunotherapy Immunoguiding Program - Cedrick Britten, PhD	Cancer Immunotherapy Immunoguiding Program - Cedrick Britten, PhD Yes	Cancer Immunotherapy Immunoguiding Program - Cedrick Britten, PhD No
Cancer Immunotherapy Consortium - Sylvia Janetzki, MD	Cancer Immunotherapy Consortium - Sylvia Janetzki, MD Yes	Cancer Immunotherapy Consortium - Sylvia Janetzki, MD No
EQAPOL (NIAID) - Tom Denny, MSc, M.Phil	EQAPOL (NIAID) - Tom Denny, MSc, M.Phil Yes	EQAPOL (NIAID) - Tom Denny, MSc, M.Phil No
FOCIS Human ImmunoPhenotyping Consortium - Holden Maecker, PhD	FOCIS Human ImmunoPhenotyping Consortium - Holden Maecker, PhD Yes	FOCIS Human ImmunoPhenotyping Consortium - Holden Maecker, PhD No

If yes, please specify

Question Title

* 32. Friday, June 28, 5:30-6:30 pm
Keynote Address: Immune Regulation by mRNA and Protein Degradation - Shizuo Akira, MD, PhD

	Disagree	Undecided	Agree	Did not attend
I will make changes in my practice/profession as a result of what I learned in this session.	I will make changes in my practice/profession as a result of what I learned in this session. Disagree	I will make changes in my practice/profession as a result of what I learned in this session. Undecided	I will make changes in my practice/profession as a result of what I learned in this session. Agree	I will make changes in my practice/profession as a result of what I learned in this session. Did not attend

Question Title

* 33. After participating in this session, are you able to:

	Yes	No
Describe the importance of MRNA decay in the immune and inflammatory reaction	Describe the importance of MRNA decay in the immune and inflammatory reaction Yes	Describe the importance of MRNA decay in the immune and inflammatory reaction No
Describe negative of immune responses by the novel Rnase	Describe negative of immune responses by the novel Rnase Yes	Describe negative of immune responses by the novel Rnase No

Question Title

* 34. Please rate the quality of this presentation.

Excellent

Good

Average

Poor

Comments

Question Title

* 35. Did you perceive bias in this presentation?

Yes

If yes, please specify

Question Title

* 36. If you would like to receive a CME certificate or certificate of attendance, please indicate below.

CME Certificate

Certificate of Attendance

Please enter your email to receive a certificate

Question Title

* 1. Please select your designation(s):

Question Title

* 2. Please indicate your specialties:

Question Title

* 3. Please select the categories you most identify with:

Question Title

* 4. Thursday, June 27, 5:30-6:30 pmOpening Keynote Address: T Cell Control of HIV - Bruce Walker, MD

Question Title

* 5. After participating in this session, are you able to:

Question Title

* 6. Please rate the quality of this presentation.

Question Title

* 7. Did you perceive bias in this presentation?

Question Title

* 8. Friday, June 28, 8:00-9:45 amPlenary Session: Targeting Signalling Pathways in Inflammatory Disease

Question Title

* 9. After participating in this session, are you able to:

Question Title

* 10. Please rate the quality of the presentations:

Question Title

* 11. Did you perceive bias in any of the session presentations?

Question Title

* 12. Friday, June 28, 10:00-11:45 amPlenary Session: Removing the Brakes on Anti-Tumor Immune Responses

Question Title

* 13. After participating in this session, are you able to:

Question Title

* 14. Please rate the quality of the session presentations:

Question Title

* 15. Did you perceive bias in any of the session presentations?

Question Title

* 16. Friday, June 28, 1:15-3:00 pmConcurrent Thematic Symposium: Innate Lymphoid Cells in Human Disease

Question Title

* 17. After participating in this session, are you able to:

Question Title

* 18. Please rate the quality of the session presentations:

Question Title

* 19. Did you perceive bias in any of the session presentations?

Question Title

* 20. Friday, June 28, 1:15-3:00 pmConcurrent Thematic Symposium: From Genes to Mechanisms

Question Title

* 21. After participating in this session, are you able to:

Question Title

* 22. Please rate the quality of the session presentations:

Question Title

* 23. Did you perceive bias in any of the session presentations?

Question Title

* 24. Friday, June 28, 1:15-3:00 pmConcurrent Thematic Symposium: B Cells in Immune Inflammation

Question Title

* 25. After participating in this session, are you able to:

Question Title

* 26. Please rate the quality of the session presentations:

Question Title

* 27. Did you perceive bias in any of the session presentations?

Question Title

* 28. Friday, June 28, 3:15-5:15 pmFeatured Course: Principles of Flow Cytometry for Immune Monitoring Part I

Question Title

* 29. After participating in this session, are you able to:

Question Title

* 30. Please rate the quality of the session presentations:

Question Title

* 31. Did you perceive bias in any of the session presentations?

Question Title

* 32. Friday, June 28, 5:30-6:30 pm Keynote Address: Immune Regulation by mRNA and Protein Degradation - Shizuo Akira, MD, PhD

Question Title

* 33. After participating in this session, are you able to:

Question Title

* 34. Please rate the quality of this presentation.

Question Title

* 35. Did you perceive bias in this presentation?

Question Title

* 36. If you would like to receive a CME certificate or certificate of attendance, please indicate below.

* 4. Thursday, June 27, 5:30-6:30 pm
Opening Keynote Address: T Cell Control of HIV - Bruce Walker, MD

* 8. Friday, June 28, 8:00-9:45 am
Plenary Session: Targeting Signalling Pathways in Inflammatory Disease

* 12. Friday, June 28, 10:00-11:45 am
Plenary Session: Removing the Brakes on Anti-Tumor Immune Responses

* 16. Friday, June 28, 1:15-3:00 pm
Concurrent Thematic Symposium: Innate Lymphoid Cells in Human Disease

* 20. Friday, June 28, 1:15-3:00 pm
Concurrent Thematic Symposium: From Genes to Mechanisms

* 24. Friday, June 28, 1:15-3:00 pm
Concurrent Thematic Symposium: B Cells in Immune Inflammation

* 28. Friday, June 28, 3:15-5:15 pm
Featured Course: Principles of Flow Cytometry for Immune Monitoring Part I

* 32. Friday, June 28, 5:30-6:30 pm
Keynote Address: Immune Regulation by mRNA and Protein Degradation - Shizuo Akira, MD, PhD